The anti-viral opportunities including COVID-19 are very...

The anti-viral opportunities including COVID-19 are very exciting. But they aren't Recce's main opportunity.

What is antimicrobial resistance?

It's the ability of a microbe to resist the effects of medication that once could successfully treat the microbe.

This includes antibiotic-resistant "superbugs". Also viruses and protozoa becoming resistant to traditional treatments.

Here are some relevant quotes to frame the AMR issue.

“No Time To Wait” – AMR Could Cause 10 Million Deaths Annually By 2050, Warns UN Report

“Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill,” says Dr Keiji Fukuda, WHO’s Assistant Director-General for Health Security.

Antimicrobial Resistance (AMR) is one of the major challenges of our time. Without effective antimicrobials, common infections will become life-threatening and treatments such as surgical procedures and chemotherapy would not be possible. – OECD Policy Brief 32

Imagine a world in which common surgeries such as appendectomies and c-sections are commonly fatal, joint replacement surgeries are too risky, and organ transplants, chemotherapy and pre-term infant care have high motality rates.

For me, the image attached below really puts the potential future of AMR into perspective (global deaths, source from WHO website).

Global annual deaths:


So what is the RCE solution?

"New Class of Synthetic Anti-Infectives that kill emerging viral pathogens as well as Gram+ & Gram– bacteria, including their superbug forms - even with repeated use!"

RECCE®327 awarded Qualified Infectious Disease Product designation under GAIN Act

• 10 years market exclusivity (post approval)
• Fast track (life of regulatory process)

327 has upcomming trials for sepsis and burns - both massive medical problems with huge addressable markets.

Both 327 and 529 invloved in COVID-19 related trials and progressing quickly with very promising results.

529 has the potential to be a world-class anti-viral.

The new 435 - an oral formulation - showing promise of addressing H. pylori, carried by up to 50% of the global population and a risk factor for stomach ulcers and gastric cancer.